Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy

Benjamin W. Teh(The University of Melbourne), Monica A. Slavin(The Royal Melbourne Hospital), Tim Spelman(Peter Doherty Institute), Leon J. Worth(The University of Melbourne), Simon J. Harrison(Peter MacCallum Cancer Centre)

British Journal of Haematology

June 24, 2015

10.1111/bjh.13532

Cited by 127

Related Papers

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

|New England Journal of Medicine|2023|719

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

|The Lancet|2019|635

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

|Leukemia|2009|586

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

|The Lancet Oncology|2020|401

Clinical Studies of Histone Deacetylase Inhibitors

|Clinical Cancer Research|2009|356